Bibliographical noteFunding Information:
Clinical research and clinical trials are a fundamental component of the BCRC, ultimately delivering the translation of laboratory-based discoveries. We also consider that changes to the patient pathway are where considerable gains can be made with the implementation of twenty-first century technologies and practices, such as non-invasive diagnosis and multiparametric MRI staging8. Clinical trial activity is supported by the University’s Cancer Research UK Clinical Trials Unit (CRCTU) and the University of Birmingham Clinical Trials Unit (BCTU).
R.T.B. has contributed to advisory boards for Olympus Medical Systems and Janssen, and undertakes research funded by UroGen Pharma, QED Therapeutics and Janssen. The other authors declare no competing interests.
Philanthropic donations to the University of Birmingham in support of bladder cancer research greatly facilitated the establishment of the Bladder Cancer Research Centre (BCRC). The authors also gratefully acknowledge the contributions made by the University of Birmingham’s Human Biomaterials Resource Centre supported through Birmingham Science City — Experimental Medicine Network of Excellence project. They are thankful to the urologists and urology nurses of the West Midlands for their considerable contributions to the recruitment and follow-up of bladder cancer study participants. They are grateful to KK Cheng for his initiation of the Bladder Cancer Prognosis Programme, D. M. A. Wallace and N. D. James for their mentorship, and D. H. Adams and P. R. Kearns for their support of the BCRC. A. Knight, Chairman of Trustees of the charity Action Bladder Cancer UK, provided a critical review of the manuscript.
ASJC Scopus subject areas